{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:25:48Z","timestamp":1788456348886,"version":"build-2803163510"},"reference-count":244,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877113"],"award-info":[{"award-number":["21877113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31300650"],"award-info":[{"award-number":["31300650"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572944"],"award-info":[{"award-number":["81572944"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.drudis.2021.04.023","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T19:21:04Z","timestamp":1619119264000},"page":"2282-2302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Mechanisms of thrombosis and research progress on targeted antithrombotic drugs"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-6486","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6290-4617","authenticated-orcid":false,"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianren","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.04.023_b0005","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamacardio.2019.0295","article-title":"Burden of cardiovascular diseases in China, 1990\u20132016: findings from the 2016 global burden of disease study","volume":"1","author":"Liu","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jcmg.2015.06.017","article-title":"Echocardiographic algorithm for post-myocardial infarction LV thrombus: a gatekeeper for thrombus evaluation by delayed enhancement CMR","volume":"9","author":"Weinsaft","year":"2016","journal-title":"JACC-Cardiovasc. Imag."},{"key":"10.1016\/j.drudis.2021.04.023_b0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12630-015-0494-9","article-title":"Perioperative stroke","volume":"63","author":"Vlisides","year":"2015","journal-title":"Can. J. Anaesth."},{"key":"10.1016\/j.drudis.2021.04.023_b0020","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1161\/STROKEAHA.117.016590","article-title":"Ischemic stroke: what does the histological composition tell us about the origin of the thrombus?","volume":"48","author":"Sporns","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2021.04.023_b0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2019.04.029","article-title":"Catheter based therapies in massive pulmonary embolism","volume":"287","author":"Patel","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1055\/s-0039-1692395","article-title":"Vascular nanomedicine: current status, opportunities, and challenges","volume":"46","author":"Sun","year":"2020","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0035","first-page":"480","article-title":"Anticoagulant therapy in the prevention and treatment of ischemic stroke","volume":"73","author":"Bauer","year":"2010","journal-title":"Cesk. Slov. Neurol. N."},{"key":"10.1016\/j.drudis.2021.04.023_b0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(15)60245-8","article-title":"Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs","volume":"386","author":"Verheugt","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.04.023_b0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamaneurol.2014.2886","article-title":"Targeted drug delivery to flow-obstructed blood vessels using mechanically activated nanotherapeutics","volume":"72","author":"Korin","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.drudis.2021.04.023_b0050","first-page":"182","article-title":"Therapeutic benefits of nanoparticles in stroke","volume":"9","author":"Panagiotou","year":"2015","journal-title":"Front. Neurosci-Switz."},{"key":"10.1016\/j.drudis.2021.04.023_b0055","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2013-03-453498","article-title":"Advanced drug delivery systems for antithrombotic agents","volume":"122","author":"Greineder","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0060","first-page":"1087","article-title":"Selective cellular expression of tissue factor in human-tissues - Implications for disorders of hemostasis and thrombosis","volume":"134","author":"Drake","year":"1989","journal-title":"AM. J. Pathol."},{"key":"10.1016\/j.drudis.2021.04.023_b0065","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood.V79.8.2039.2039","article-title":"Factor-IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo","volume":"79","author":"Bauer","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2007-994012","article-title":"Fibrinogen: its role in the hemostatic regulation in atherosclerosis","volume":"19","author":"Eber","year":"1993","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0075","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/10408360590951171","article-title":"Molecular aspects of thrombosis and antithrombotic drugs","volume":"42","author":"Wu","year":"2005","journal-title":"Crit. Rev. Cl. Lab. Sci."},{"key":"10.1016\/j.drudis.2021.04.023_b0085","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein-coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2021.04.023_b0090","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/ATVBAHA.110.207522","article-title":"Signaling during platelet adhesion and activation","volume":"30","author":"Li","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2021.04.023_b0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-018-0259-z","article-title":"Structural insights into G-protein-coupled receptor allostery","volume":"559","author":"Thal","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lfs.2003.09.010","article-title":"Proteinase-mediated signaling: proteinase-activated receptors (PARs) and much more","volume":"74","author":"Hollenberg","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2021.04.023_b0105","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature14287","article-title":"Two disparate ligand-binding sites in the human P2Y1 receptor","volume":"520","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0110","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0735-1097(99)00443-X","article-title":"Clopidogrel as adjunctive antiplatelet therapy during coronary stenting","volume":"34","author":"Mishkel","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.vph.2014.06.001","article-title":"Functional role of protease activated receptors in vascular biology","volume":"62","author":"Alberelli","year":"2014","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.drudis.2021.04.023_b0120","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/29325","article-title":"A dual thrombin receptor system for platelet activation","volume":"394","author":"Kahn","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0125","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/35007085","article-title":"PAR3 is a cofactor for PAR4 activation by thrombin","volume":"404","author":"Nakanishi-Matsui","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.pharmtox.37.1.167","article-title":"G protein beta gamma subunits","volume":"37","author":"Clapham","year":"1997","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drudis.2021.04.023_b0135","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/ATVBAHA.114.303412","article-title":"G-protein-coupled receptors signaling pathways in new antiplatelet drug development","volume":"35","author":"Gurbe","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2021.04.023_b0140","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1083\/jcb.200207119","article-title":"Intercellular calcium communication regulates platelet aggregation and thrombus growth","volume":"160","author":"Nesbitt","year":"2003","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.drudis.2021.04.023_b0145","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1021\/bi9927078","article-title":"Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets","volume":"39","author":"Covic","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2021.04.023_b0150","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature22309","article-title":"Structural insight into allosteric modulation of protease-activated receptor 2","volume":"545","author":"Cheng","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0155","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pharmthera.2011.01.003","article-title":"Structure, function and pathophysiology of protease activated receptors","volume":"130","author":"Adams","year":"2011","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.drudis.2021.04.023_b0160","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/j.1538-7836.2008.03052.x","article-title":"Formation of coated platelets is regulated by the dense granule secretion of adenosine 5\u2019diphosphate acting via the P2Y12 receptor","volume":"6","author":"Kotova","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0165","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","article-title":"The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity","volume":"110","author":"Storey","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drudis.2021.04.023_b0170","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1126\/science.1174779","article-title":"G protein subunit G alpha13 binds to integrin alpha(iib)beta 3 and mediates integrin \u2018outside-in\u2019 signaling","volume":"327","author":"Gong","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.04.023_b0175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.blre.2011.03.002","article-title":"Platelets at work in primary hemostasis","volume":"25","author":"Broos","year":"2011","journal-title":"Blood Rev."},{"key":"10.1016\/j.drudis.2021.04.023_b0180","doi-asserted-by":"crossref","first-page":"C373","DOI":"10.1152\/ajpcell.00325.2015","article-title":"Oral administration of Bruton\u2019s tyrosine kinase inhibitors impairs GPVI-mediated platelet function","volume":"310","author":"Rigg","year":"2016","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0185","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2002-12-3882","article-title":"Platelet-collagen interaction: is GPVI the central receptor?","volume":"102","author":"Nieswandt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0190","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A role for Bruton\u2019s tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr. Biol."},{"key":"10.1016\/j.drudis.2021.04.023_b0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ajh.21363","article-title":"Balancing role of nitric oxide in complement-mediated activation of platelets from mCd59a and mCd59b double-knockout mice","volume":"84","author":"Qin","year":"2009","journal-title":"Am J. Hematol."},{"key":"10.1016\/j.drudis.2021.04.023_b0200","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1042\/bj2820409","article-title":"Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes","volume":"282","author":"Morgan","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.drudis.2021.04.023_b0205","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1182\/blood-2009-04-218768","article-title":"CalDAG-GEFI is at the nexus of calcium-dependent platelet activation","volume":"114","author":"Stefanini","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.drudis.2021.04.023_b0210","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nm.1955","article-title":"A shear gradient-dependent platelet aggregation mechanism drives thrombus formation","volume":"15","author":"Nesbitt","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b0215","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/cvr\/cvt110","article-title":"The effects of arterial flow on platelet activation, thrombus growth, and stabilization","volume":"99","author":"Cosemans","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.drudis.2021.04.023_b0220","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/44599","article-title":"Integrin cytoplasmic tyrosine motif is required for outside-in alpha IIb beta 3 signalling and platelet function","volume":"401","author":"Law","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0225","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1074\/jbc.M709527200","article-title":"The N-terminal domains of talin cooperate with the phosphotyrosine binding-like domain to activate beta 1 and beta 3 integrins","volume":"283","author":"Bouaouina","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.023_b0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.1086652","article-title":"Talin binding to integrin beta tails: a final common step in integrin activation","volume":"302","author":"Tadokoro","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.04.023_b0235","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature02976","article-title":"Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics","volume":"432","author":"Xiao","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0240","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1182\/blood.V97.9.2648","article-title":"Fibrinogen binding to the integrin alpha(IIb)beta(3; modulates store-mediated calcium entry in human platelets","volume":"97","author":"Rosado","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0245","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V74.1.182.182","article-title":"Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa\/IIa and an indirect interaction with platelet GPIIb\/IIIa mediated by adhesive proteins","volume":"74","author":"Coller","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0250","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4161\/cam.5.1.13559","article-title":"Integrin \u03b1IIb\u03b23: a novel effector of G\u03b113","volume":"5","author":"Chari-Turaga","year":"2011","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.drudis.2021.04.023_b0255","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nature12613","article-title":"A directional switch of integrin signalling and a new anti-thrombotic strategy","volume":"503","author":"Shen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0260","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ceb.2012.08.011","article-title":"Inside-out, outside-in, and inside-outside-in: G protein signaling in integrin-mediated cell adhesion, spreading, and retraction","volume":"24","author":"Shen","year":"2012","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.drudis.2021.04.023_b0265","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2004-04-1257","article-title":"Integrins: dynamic scaffolds for adhesion and signaling in platelets","volume":"104","author":"Shattil","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0270","doi-asserted-by":"crossref","first-page":"15868","DOI":"10.1016\/S0021-9258(18)82334-1","article-title":"Tyrosine phosphorylation and cytoskeletal reorganization in platelets are triggered by interaction of integrin receptors with their immobilized ligands","volume":"268","author":"Haimovich","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.023_b0275","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.bbagen.2015.09.013","article-title":"Modulation and pre-amplification of PAR1 signaling by ADP acting via the P2Y12 receptor during platelet subpopulation formation","volume":"1850","author":"Shakhidzhanov","year":"2015","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.drudis.2021.04.023_b0280","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI12242","article-title":"Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs","volume":"107","author":"Foster","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2021.04.023_b0285","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1538-7836.2009.03722.x","article-title":"Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation","volume":"8","author":"Harper","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0290","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1042\/BJ20060822","article-title":"Calmodulin interacts with the platelet ADP receptor P2Y1","volume":"398","author":"Arthur","year":"2006","journal-title":"Biochem. J."},{"key":"10.1016\/j.drudis.2021.04.023_b0295","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2003-05-1385","article-title":"Platelet ADP receptors contribute to the initiation of intravascular coagulation","volume":"103","author":"Leon","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0300","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1538-7836.2006.01849.x","article-title":"P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation","volume":"4","author":"Erhardt","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0305","doi-asserted-by":"crossref","unstructured":"Remijn JA, Wu YP, Jeninga EH, IJsseldijk MJ, van Willigen G, de Groot PG et al. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 686\u201391","DOI":"10.1161\/01.ATV.0000012805.49079.23"},{"key":"10.1016\/j.drudis.2021.04.023_b0310","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2002-01-0313","article-title":"To the editor: adenosine diphosphate (ADP) does not induce thromboxane A2 generation in human platelets","volume":"99","author":"Cattaneo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0315","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1073\/pnas.95.14.8070","article-title":"Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation","volume":"95","author":"Jin","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drudis.2021.04.023_b0320","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/blood-2006-03-006338","article-title":"Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization","volume":"108","author":"Cosemans","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0325","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/13522","article-title":"Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice","volume":"5","author":"Fabre","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b0330","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature13083","article-title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0335","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2741\/1939","article-title":"The role of ADP receptors in platelet function","volume":"11","author":"Murugappan","year":"2006","journal-title":"Front. Biosci-Landmrk"},{"key":"10.1016\/j.drudis.2021.04.023_b0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1096\/fasebj.3.1.2642868","article-title":"Endothelium-derived nitric oxide: actions and properties","volume":"3","author":"Ignarro","year":"1989","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2021.04.023_b0345","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2006.12.011","article-title":"Hydrogen sulfide inhibits human platelet aggregation","volume":"559","author":"Zagli","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2021.04.023_b0350","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3389\/fphar.2018.01066","article-title":"Hydrogen sulfide (H2S)-releasing compounds: therapeutic potential in cardiovascular diseases","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2021.04.023_b0355","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1166\/jbn.2014.2014","article-title":"Effects of shear stress on endothelial progenitor cells","volume":"10","author":"Obi","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.drudis.2021.04.023_b0360","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1182\/blood-2011-12-398149","article-title":"Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis","volume":"119","author":"Zaitsev","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0365","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2044.2005.04192.x","article-title":"Direct thrombin inhibitors: pharmacology and clinical relevance","volume":"60","author":"Kam","year":"2005","journal-title":"Anaesthesia"},{"key":"10.1016\/j.drudis.2021.04.023_b0370","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.2146\/ajhp070624","article-title":"Rivaroxaban: an oral direct inhibitor of factor Xa","volume":"65","author":"Gulseth","year":"2008","journal-title":"Am. J. Health-Syst. Ph."},{"key":"10.1016\/j.drudis.2021.04.023_b0375","doi-asserted-by":"crossref","first-page":"37186","DOI":"10.18632\/oncotarget.16427","article-title":"Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2021.04.023_b0380","article-title":"Nonhemostatic activities of factor Xa: are there pleiotropic effects of anti-FXa direct oral anticoagulants?","volume":"3319719840861","author":"Papadaki","year":"2019","journal-title":"Angiology"},{"key":"10.1016\/j.drudis.2021.04.023_b0385","doi-asserted-by":"crossref","first-page":"14349","DOI":"10.1038\/srep14349","article-title":"A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2021.04.023_b0390","doi-asserted-by":"crossref","first-page":"70s","DOI":"10.1016\/S0735-1097(02)02687-6","article-title":"The evolving role of direct thrombin inhibitors in acute coronary syndromes","volume":"41","author":"Eikelboom","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0395","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/bj1930395","article-title":"The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin","volume":"193","author":"Holmer","year":"1981","journal-title":"Biochem. J."},{"key":"10.1016\/j.drudis.2021.04.023_b0400","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1021\/bi012163l","article-title":"Importance of Lysine 125 for heparin binding and activation of antithrombin","volume":"41","author":"Schedin-Weiss","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2021.04.023_b0405","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/00000539-200111000-00007","article-title":"Resuscitation with Hextend((R)) decreases endogenous circulating heparin activity and accelerates clot initiation after hemorrhage in the rabbit","volume":"93","author":"Nielsen","year":"2001","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.drudis.2021.04.023_b0410","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/18877","article-title":"Synthesis of thrombin-inhibiting heparin mimetics without side effects","volume":"398","author":"Petitou","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114094","article-title":"Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems","volume":"178","author":"Tacconelli","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2021.04.023_b0420","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","author":"Farid","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2021.04.023_b0425","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2011.01.058","article-title":"The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs","volume":"657","author":"Kogushi","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2021.04.023_b0430","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.CIR.98.11.1085","article-title":"Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb\/IIIa and alpha(v)beta3 integrins","volume":"98","author":"Tam","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.023_b0435","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0049-3848(02)00207-4","article-title":"The GP IIb\/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b\/CD18: alpha M beta(2))","volume":"107","author":"Schwarz","year":"2002","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2021.04.023_b0440","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action","volume":"12","author":"Patrignani","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0445","doi-asserted-by":"crossref","first-page":"B11","DOI":"10.1016\/0002-9149(91)90379-Y","article-title":"Mechanisms of platelet activation - thromboxane-A2 as an amplifying signal for other agonists","volume":"68","author":"Fitzgerald","year":"1991","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0450","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/13543784.13.5.457","article-title":"Effects of ADP-receptor antagonism beyond traditional inhibition of platelet aggregation","volume":"13","author":"Herbert","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2021.04.023_b0455","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.pharmtox.46.120604.141207","article-title":"Regulation of platelet functions by P2 receptors","volume":"46","author":"Gachet","year":"2006","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drudis.2021.04.023_b0460","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1538-7836.2008.03136.x","article-title":"Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor","volume":"6","author":"Algaier","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0465","doi-asserted-by":"crossref","first-page":"21167","DOI":"10.1073\/pnas.0906436106","article-title":"Molecular priming of Lyn by GPVI enables an immune receptor to adopt a hemostatic role","volume":"106","author":"Schmaier","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drudis.2021.04.023_b0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/09537100400005634","article-title":"Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes","volume":"16","author":"Behan","year":"2005","journal-title":"Platelets"},{"key":"10.1016\/j.drudis.2021.04.023_b0475","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/107602969600200108","article-title":"Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets","volume":"2","author":"Savi","year":"1996","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0480","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.atherosclerosis.2014.08.045","article-title":"A new mechanism of action of thienopyridine antiplatelet drugs - a role for gastric nitrosthiol metabolism?","volume":"237","author":"Anderson","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2021.04.023_b0485","doi-asserted-by":"crossref","first-page":"14368","DOI":"10.1074\/jbc.274.20.14368","article-title":"Nitric oxide inhibits thrombin-receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets","volume":"274","author":"Pigazzi","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.023_b0490","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1073\/pnas.0510446103","article-title":"The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts","volume":"103","author":"Savi","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drudis.2021.04.023_b0495","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1160\/TH08-12-0805","article-title":"The in-vitro effects of E5555: a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease","volume":"102","author":"Serebruany","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0500","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1517\/13543784.2010.521741","article-title":"Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events","volume":"19","author":"Tomasello","year":"2010","journal-title":"Expert. Opin. Investig. Drugs."},{"key":"10.1016\/j.drudis.2021.04.023_b0505","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.me.37.020186.001341","article-title":"In vivo diagnostic and therapeutic uses of monoclonal antibodies in cardiology","volume":"37","author":"Haber","year":"1986","journal-title":"Ann. Rev. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b0510","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal-antibody directed against the platelet glycoprotein iib\/iiia receptor in high-risk coronary angioplasty","volume":"330","author":"Investigators","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b0515","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/bmm.10.119","article-title":"Glycoprotein IIb\/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy","volume":"5","author":"Lippi","year":"2011","journal-title":"Biomark. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b0520","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000026","article-title":"P2Y12 receptor blockade augments glycoprotein Iib-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity","volume":"2","author":"Berny-Lang","year":"2013","journal-title":"J Am. Heart Assoc."},{"key":"10.1016\/j.drudis.2021.04.023_b0525","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.023_b0530","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/17425247.2018.1384464","article-title":"Tissue plasminogen activator-based nanothrombolysis for ischemic stroke","volume":"15","author":"Liu","year":"2018","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.drudis.2021.04.023_b0535","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1074\/jbc.270.19.11205","article-title":"The significance of fibrin binding by plasminogen-activator inhibitor-1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis","volume":"270","author":"Stringer","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.023_b0540","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2010-06-290338","article-title":"The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies","volume":"117","author":"Longstaff","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0545","doi-asserted-by":"crossref","first-page":"12994","DOI":"10.1016\/S0021-9258(18)98794-6","article-title":"Domain structure and domain-domain interactions of recombinant tissue plasminogen activator","volume":"266","author":"Novokhatny","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.023_b0550","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.amjcard.2007.07.051","article-title":"Results of percutaneous coronar intervention of the unprotected left main coronary artery in 143 patients and comparison of 30-day mortality to results of coronary artery bypass grafting","volume":"101","author":"Dubois","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0555","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.athoracsur.2006.03.074","article-title":"Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery","volume":"82","author":"Ward","year":"2006","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.drudis.2021.04.023_b0560","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1053\/hj.1999.v138.99077","article-title":"Platelet glycoprotein IIb\/IIIa antagonists in percutaneous coronary revascularization","volume":"138","author":"Dangas","year":"1999","journal-title":"Am. Heart. J."},{"key":"10.1016\/j.drudis.2021.04.023_b0565","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/heartjnl-2018-314381","article-title":"Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis","author":"Beggs","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.drudis.2021.04.023_b0570","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11239-007-0110-0","article-title":"Dietary supplements, herbs and oral anticoagulants: the nature of the evidence","volume":"25","author":"Wittkowsky","year":"2008","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.drudis.2021.04.023_b0575","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1253\/circj.CJ-18-0872","article-title":"Current status, time trends and outcomes of combination therapy with oral anticoagulant and antiplatelet drug in patients with atrial fibrillation - The Fushimi AF Registry","volume":"82","author":"Masunaga","year":"2018","journal-title":"Circ. J."},{"key":"10.1016\/j.drudis.2021.04.023_b0580","doi-asserted-by":"crossref","first-page":"230","DOI":"10.11622\/smedj.2018051","article-title":"Traditional Chinese medicine: herb-drug interactions with aspirin","volume":"59","author":"Lim","year":"2018","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.drudis.2021.04.023_b0585","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.2174\/138161206779010440","article-title":"Drug-herb interactions: eliminating toxicity with hard drug design","volume":"12","author":"Yang","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2021.04.023_b0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2017.11.012","article-title":"Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism","volume":"97","author":"Riva","year":"2018","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0595","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.molpharmaceut.8b01325","article-title":"Novel strategy of gene delivery system based on dendrimer loaded recombinant hirudine plasmid for thrombus targeting therapy","volume":"16","author":"Chen","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2021.04.023_b0600","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0142-9612(83)90063-7","article-title":"On the mechanism of enhanced thromboresistance of polymeric materials in the presence of heparin","volume":"4","author":"Plate","year":"1983","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.04.023_b0605","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1016\/0006-2952(85)90350-8","article-title":"Antithrombotic and bleeding effects of a low molecular weight heparin fraction","volume":"34","author":"Pangrazzi","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2021.04.023_b0610","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2021.04.023_b0615","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1160\/TH06-05-0234","article-title":"Emerging anticoagulants for the treatment of venous thromboembolism","volume":"96","author":"Weitz","year":"2006","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0620","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14281","article-title":"Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity","volume":"16","author":"Carter","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0625","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b0630","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.ijcard.2012.08.014","article-title":"Novel oral anticoagulants in acute coronary syndrome","volume":"167","author":"Costopoulos","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0635","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nm.3157","article-title":"Blocking bleeding: reversing anticoagulant therapy","volume":"19","author":"Ansell","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b0640","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pharmthera.2012.02.006","article-title":"Novel antithrombotic agents for atrial fibrillation","volume":"134","author":"Niespialowska-Steuden","year":"2012","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.drudis.2021.04.023_b0645","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"Schror","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0650","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CRD.0b013e3182099d86","article-title":"Ticagrelor a novel reversible oral antiplatelet agent","volume":"19","author":"Nawarskas","year":"2011","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.drudis.2021.04.023_b0655","doi-asserted-by":"crossref","first-page":"22390","DOI":"10.1016\/j.matpr.2018.06.607","article-title":"Cyclic voltammertic studies of invitro interaction of clopidogrel bisulphate and asprin","volume":"5","author":"Raj","year":"2018","journal-title":"Mater. Today-Proc."},{"key":"10.1016\/j.drudis.2021.04.023_b0660","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1160\/TH08-07-0456","article-title":"Rehfuss R Clopidogrel versus prassugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability","volume":"101","author":"Wong","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0665","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/cvr\/cvw233","article-title":"Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression","volume":"113","author":"Reiner","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.drudis.2021.04.023_b0670","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","article-title":"Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial","volume":"123","author":"O'Donoghue","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.023_b0675","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","article-title":"Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial","volume":"123","author":"Wiviott","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.023_b0680","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/STROKEAHA.108.539197","article-title":"Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization single center experience in 42 cases and review of the literature","volume":"40","author":"Ries","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2021.04.023_b0685","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jcin.2010.05.017","article-title":"Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes","volume":"3","author":"Prati","year":"2010","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.drudis.2021.04.023_b0690","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4155\/fmc-2017-0001","article-title":"The progress in the research of antiplatelet agents (1995\u20132017)","volume":"9","author":"Benimana","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.drudis.2021.04.023_b0695","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1111\/jth.12947","article-title":"Antiplatelet drugs: which targets for which treatments?","volume":"13","author":"Gachet","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0700","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40264-016-0443-8","article-title":"Drug interactions of direct-acting oral anticoagulants","volume":"39","author":"Fitzgerald","year":"2016","journal-title":"Drug Safety"},{"key":"10.1016\/j.drudis.2021.04.023_b0705","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00063030-199911020-00005","article-title":"Pharmacokinetics of the recombinant thrombolytic agents - what is the clinical significance of their different pharmacokinetic parameters?","volume":"11","author":"Cohen","year":"1999","journal-title":"Biodrugs"},{"key":"10.1016\/j.drudis.2021.04.023_b0710","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1747-4949.2012.00923.x","article-title":"Thrombolysis in the developing world: is there a role for streptokinase?","volume":"8","author":"Butcher","year":"2013","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.drudis.2021.04.023_b0715","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1007\/s00253-018-9402-x","article-title":"Engineering of deglycosylated and plasmin resistant variants of recombinant streptokinase in Pichia pastoris","volume":"102","author":"Adivitiya","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.drudis.2021.04.023_b0720","article-title":"Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction","volume":"1386\u201393","author":"S\u00f6rensen","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0725","doi-asserted-by":"crossref","first-page":"32988","DOI":"10.1021\/acsami.8b09423","article-title":"Tissue plasminogen activator-porous magnetic microrods for targeted thrombolytic therapy after ischemic stroke","volume":"10","author":"Hu","year":"2018","journal-title":"ACS Appl. Mater. Inter."},{"key":"10.1016\/j.drudis.2021.04.023_b0730","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1538-7836.2007.02422.x","article-title":"The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1","volume":"5","author":"Thelwell","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0735","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199700543-00004","article-title":"Evaluation of thrombolytic agents","volume":"54","author":"Bell","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2021.04.023_b0740","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0002-9343(00)00380-6","article-title":"Third-generation thrombolytic drugs","volume":"109","author":"Verstraete","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b0745","doi-asserted-by":"crossref","unstructured":"Su HB, Zhang YG, He JT, Mo W, Zhang YL, Tao XM et al. Construction and characterization of novel staphylokinase variants with antiplatelet aggregation activity and reduced immunogenecity. Acta Biochim. Biophys. Sin. (Shanghai). 2004; 36: 336\u201342","DOI":"10.1093\/abbs\/36.5.336"},{"key":"10.1016\/j.drudis.2021.04.023_b0750","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11239-016-1334-7","article-title":"In vitro fibrinolysis and antithrombosis characterizations of novel recombinant microplasminogen with RGD and GPRP peptides","volume":"42","author":"Chen","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.drudis.2021.04.023_b0755","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1016\/j.biomaterials.2010.03.055","article-title":"EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery","volume":"31","author":"Mei","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.04.023_b0760","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1016\/j.biomaterials.2009.02.034","article-title":"Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles","volume":"30","author":"Ma","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.04.023_b0765","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1007\/s12274-016-1152-4","article-title":"Magnetically active Fe3O4 nanorods loaded with tissue plasminogen activator for enhanced thrombolysis","volume":"9","author":"Hu","year":"2016","journal-title":"Nano Res."},{"key":"10.1016\/j.drudis.2021.04.023_b0770","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.2147\/IJN.S36197","article-title":"Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle","volume":"7","author":"Chen","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.drudis.2021.04.023_b0775","doi-asserted-by":"crossref","first-page":"32c","DOI":"10.1016\/S0002-9149(00)00877-8","article-title":"The use of glycoprotein IIb\/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends","volume":"85","author":"Campbell","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.023_b0780","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biomaterials.2017.03.012","article-title":"Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis","volume":"128","author":"Pawlowski","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.04.023_b0785","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/01.CIR.101.10.1158","article-title":"Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa","volume":"101","author":"Peter","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.023_b0790","doi-asserted-by":"crossref","unstructured":"Duggan ME, Naylor-Olsen AM, Perkins JJ, Anderson PS, Chang CT, Cook JJ et al. Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. J. Med. Chem. 1995; 38: 3332\u201341","DOI":"10.1021\/jm00017a017"},{"key":"10.1016\/j.drudis.2021.04.023_b0795","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/01.CIR.89.1.3","article-title":"Antiplatelet and antithrombotic efficacy of DMP 728: a novel platelet GPIIb\/IIIa receptor antagonist","volume":"89","author":"Mousa","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.023_b0800","doi-asserted-by":"crossref","first-page":"7664","DOI":"10.1021\/nn402171v","article-title":"Nanosized aspirin-Arg-Gly-Asp-Val: delivery of aspirin to thrombus by the target carrier Arg-Gly-Asp-Val tetrapeptide","volume":"7","author":"Jin","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2021.04.023_b0805","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4155\/tde-2017-0026","article-title":"Liposomes for the delivery of streptokinase","volume":"8","author":"Kumar","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.drudis.2021.04.023_b0810","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1160\/TH06-10-0562","article-title":"A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant","volume":"97","author":"Szemraj","year":"2007","journal-title":"An in-vivo study. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b0815","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.actbio.2018.01.038","article-title":"Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis","volume":"70","author":"Zhang","year":"2018","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/j.drudis.2021.04.023_b0820","article-title":"Targeting interstitial myofibroblast-expressed integrin alphavbeta3 alleviates renal fibrosis","volume":"1373\u201385","author":"Zhou","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2021.04.023_b0825","doi-asserted-by":"crossref","first-page":"21612","DOI":"10.1074\/jbc.270.37.21612","article-title":"Requirement for the synergy site for cell adhesion to fibronectin depends on the activation state of integrin alpha 5 beta 1","volume":"270","author":"Danen","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.023_b0830","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0168-3659(01)00335-2","article-title":"Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature","volume":"74","author":"Hallahan","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2021.04.023_b0835","doi-asserted-by":"crossref","first-page":"21255","DOI":"10.1039\/D0NR03633A","article-title":"Combination targeting of \u2018platelets + fibrin\u2019 enhances clot anchorage efficiency of nanoparticles for vascular drug delivery","volume":"12","author":"Sun","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.drudis.2021.04.023_b0840","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2020.11.034","article-title":"Reprogramming the rapid clearance of thrombolytics by nanoparticle encapsulation and anchoring to circulating red blood cells","volume":"329","author":"Singh","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2021.04.023_b0845","doi-asserted-by":"crossref","unstructured":"Nan D, Jin H, Yang D, Yu W, Jia J, Yu Zet al. Combination of polyethylene glycol-conjugated urokinase nanogels and urokinase for acute ischemic stroke therapeutic implications. Transl. Stroke Res. Published online October 26, 2020. http:\/\/dx.doi.org\/10.1007\/s12975-12020-00865-12972","DOI":"10.1007\/s12975-020-00865-2"},{"key":"10.1016\/j.drudis.2021.04.023_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120297","article-title":"Nanomedicine progress in thrombolytic therapy","volume":"258","author":"Zenych","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.04.023_b0855","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/17425247.2017.1316262","article-title":"The effects of particle size, shape, density and flow characteristics on particle margination to vascular walls in cardiovascular diseases","volume":"15","author":"Ta","year":"2018","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.drudis.2021.04.023_b0860","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1021\/nn5061578","article-title":"Engineering poly(ethylene glycol) particles for improved biodistribution","volume":"9","author":"Cui","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2021.04.023_b0865","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/anie.201408529","article-title":"Targeted antithrombotic protein micelles","volume":"54","author":"Kim","year":"2015","journal-title":"Angew. Chem. Int. Edit."},{"key":"10.1016\/j.drudis.2021.04.023_b0870","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1016\/j.biomaterials.2013.02.013","article-title":"The delivery of thrombi-specific nanoparticles incorporating oligonucleotides into injured cerebrovascular endothelium","volume":"34","author":"Shi","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.04.023_b0875","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1016\/j.biomaterials.2012.06.094","article-title":"A tissue factor targeted nanomedical system for thrombi-specific drug delivery","volume":"33","author":"Shi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.04.023_b0880","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1474-4422(15)70017-7","article-title":"Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2: randomised, open-label, blinded endpoint study","volume":"14","author":"Huang","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2021.04.023_b0885","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/01.STR.0000251788.03914.00","article-title":"Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients","volume":"38","author":"Lee","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2021.04.023_b0890","doi-asserted-by":"crossref","first-page":"42525","DOI":"10.1021\/acsami.7b12689","article-title":"Phase transition nanoparticles as multimodality contrast agents for the detection of thrombi and for targeting thrombolysis: in vitro and in vivo experiments","volume":"9","author":"Xu","year":"2017","journal-title":"ACS Appl. Mater. Inter."},{"key":"10.1016\/j.drudis.2021.04.023_b0895","first-page":"5159","article-title":"Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis","volume":"7","author":"Yang","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.drudis.2021.04.023_b0900","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3390\/ijms18091837","article-title":"Synthesis and characterization of tissue plasminogen activator-functionalized superparamagnetic iron oxide nanoparticles for targeted fibrin clot dissolution","volume":"18","author":"Heid","year":"2017","journal-title":"Int. J Mol. Sci."},{"key":"10.1016\/j.drudis.2021.04.023_b0905","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1196\/annals.1380.034","article-title":"Nanomedicine opportunities in cardiology","volume":"1080","author":"Lanza","year":"2006","journal-title":"Ann. NY. Acad. Sci."},{"key":"10.1016\/j.drudis.2021.04.023_b0910","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jmmm.2006.10.1204","article-title":"Intra-arterial application of magnetic nanoparticles for targeted thrombolytic therapy: a rat embolic model","volume":"311","author":"Ma","year":"2007","journal-title":"J. Magn. Magn. Mater."},{"key":"10.1016\/j.drudis.2021.04.023_b0915","doi-asserted-by":"crossref","first-page":"30040","DOI":"10.1021\/acsami.8b10129","article-title":"Magnetite nanocontainers: toward injectable highly magnetic materials for targeted drug delivery","volume":"10","author":"Anastasova","year":"2018","journal-title":"ACS Appl. Mater. Inter."},{"key":"10.1016\/j.drudis.2021.04.023_b0920","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/01.CIR.98.13.1268","article-title":"Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb\/IIIa receptor blockade with oral xemilofiban - Rresults of a multicenter, placebo-controlled, randomized trial","volume":"98","author":"Kereiakes","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.023_b0925","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ultras.2010.09.001","article-title":"Platelet-targeted microbubbles inhibit re-occlusion after thrombolysis with transcutaneous ultrasound and microbubbles","volume":"51","author":"Zhou","year":"2011","journal-title":"Ultrasonics"},{"key":"10.1016\/j.drudis.2021.04.023_b0930","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1161\/01.STR.0000140890.86779.79","article-title":"Intracranial clot lysis with intravenous microbubbles and transcranial ultrasound in swine","volume":"35","author":"Culp","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2021.04.023_b0935","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99329","article-title":"Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis","volume":"3","author":"Hanjaya-Putra","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2021.04.023_b0940","first-page":"111","article-title":"A single-chain antibody-CD39 fusion protein targeting activated platelets protects from cardiac ischaemia\/reperfusion injury","volume":"39","author":"Ziegler","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2021.04.023_b0945","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.7150\/thno.19900","article-title":"Targeting activated platelets: a unique and potentially universal approach for cancer imaging","volume":"7","author":"Yap","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2021.04.023_b0950","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.108.825067","article-title":"Diagnostic ultrasound combined with glycoprotein IIb\/IIIa-targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions","volume":"119","author":"Xie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.023_b0955","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/01.CIR.99.19.2577","article-title":"Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb\/IIIa-dependent mechanism","volume":"99","author":"Merten","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.023_b0960","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1515\/cclm-2016-0895","article-title":"The clinical significance of platelet microparticle-associated microRNAs","volume":"55","author":"Provost","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b0965","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/17425241003610633","article-title":"Drug delivery by red blood cells: vascular carriers designed by mother nature","volume":"7","author":"Muzykantov","year":"2010","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.drudis.2021.04.023_b0970","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.addr.2016.02.007","article-title":"Red blood cells: supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems","volume":"106","author":"Villa","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.drudis.2021.04.023_b0975","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/pharmaceutics12050440","article-title":"Vascular drug delivery using carrier red blood cells: focus on RBC surface loading and pharmacokinetics","volume":"12","author":"Glassman","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2021.04.023_b0980","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tmrv.2016.08.004","article-title":"Erythrocytes as carriers for drug delivery in blood transfusion and beyond","volume":"31","author":"Villa","year":"2017","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.drudis.2021.04.023_b0985","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/pharmaceutics12050435","article-title":"Erythrocytes as carriers of therapeutic enzymes","volume":"12","author":"Bax","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2021.04.023_b0990","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.2019001643","article-title":"Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways","volume":"135","author":"Noubouossie","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b0995","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1096\/fj.201600912R","article-title":"Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury","volume":"31","author":"Carnemolla","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2021.04.023_b1000","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/bloodadvances.2017011734","article-title":"Biocompatible coupling of therapeutic fusion proteins to human erythrocytes","volume":"2","author":"Villa","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.drudis.2021.04.023_b1005","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1182\/blood-2010-01-261610","article-title":"Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation","volume":"115","author":"Zaitsev","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b1010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0304-4165(86)90184-4","article-title":"Immunotargeting of erythrocyte-bound streptokinase provides local lysis of a fibrin clot","volume":"884","author":"Muzykantov","year":"1986","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.drudis.2021.04.023_b1015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/abio.1996.0384","article-title":"Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin","volume":"241","author":"Muzykantov","year":"1996","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.drudis.2021.04.023_b1020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0014-5793(93)80002-C","article-title":"Avidin attachment to biotinylated amino groups of the erythrocyte membrane eliminates homologous restriction of both classical and alternative pathways of the complement","volume":"318","author":"Muzykantov","year":"1993","journal-title":"FEBS Letters"},{"key":"10.1016\/j.drudis.2021.04.023_b1025","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood.V78.10.2611.2611","article-title":"Avidin attachment to biotinylated erythrocytes induces homologous lysis via the alternative pathway of complement","volume":"78","author":"Muzykantov","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b1030","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1161\/CIRCULATIONAHA.107.750257","article-title":"Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator","volume":"118","author":"Danielyan","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.023_b1035","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nbt846","article-title":"Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes","volume":"21","author":"Murciano","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2021.04.023_b1040","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1124\/jpet.104.075770","article-title":"Blood clearance and activity of erythrocyte-coupled fibrinolytics","volume":"312","author":"Ganguly","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2021.04.023_b1045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1124\/jpet.106.114405","article-title":"The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition","volume":"321","author":"Ganguly","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2021.04.023_b1050","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1182\/blood-2010-10-310409","article-title":"Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent","volume":"117","author":"Gersh","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b1055","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1124\/jpet.109.159194","article-title":"Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis","volume":"332","author":"Zaitsev","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2021.04.023_b1060","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1538-7836.2010.03802.x","article-title":"The spatial dynamics of fibrin clot dissolution catalysed by erythrocyte-bound vs. free fibrinolytics","volume":"8","author":"Gersh","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b1065","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2009.07.003","article-title":"Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile","volume":"139","author":"Murciano","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2021.04.023_b1070","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1124\/jpet.105.093450","article-title":"Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo","volume":"316","author":"Ganguly","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2021.04.023_b1075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.expneurol.2011.10.029","article-title":"Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan","volume":"233","author":"Pisapia","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2021.04.023_b1080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12975-011-0105-1","article-title":"RBC-coupled tPA prevents whereas tPA aggravates JNK MAPK-mediated impairment of ATP- and Ca-sensitive K channel-mediated cerebrovasodilation after cerebral photothrombosis","volume":"3","author":"Armstead","year":"2012","journal-title":"Transl. Stroke Res."},{"key":"10.1016\/j.drudis.2021.04.023_b1085","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1097\/PCC.0b013e3181fe40a7","volume":"12","author":"Armstead","year":"2011","journal-title":"Pediatr. Crit Care. Med."},{"key":"10.1016\/j.drudis.2021.04.023_b1090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1471-4159.2010.06613.x","article-title":"Signaling, delivery and age as emerging issues in the benefit\/risk ratio outcome of tPA For treatment of CNS ischemic disorders","volume":"113","author":"Armstead","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2021.04.023_b1095","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1089\/neu.2008.0720","article-title":"Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury","volume":"26","author":"Stein","year":"2009","journal-title":"J. Neurotraum."},{"key":"10.1016\/j.drudis.2021.04.023_b1100","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/jcbfm.2009.61","article-title":"Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia\/ischemia through inhibition of ERK MAPK activation","volume":"29","author":"Armstead","year":"2009","journal-title":"J Cereb. Blood F. Met."},{"key":"10.1016\/j.drudis.2021.04.023_b1105","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1038\/s41467-019-12897-w","article-title":"The transcription factor ERG regulates a low shear stress-induced anti-thrombotic pathway in the microvasculature","volume":"10","author":"Peghaire","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drudis.2021.04.023_b1110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.addr.2020.06.013","article-title":"Targeting drug delivery in the vascular system: focus on endothelium","volume":"157","author":"Glassman","year":"2020","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.drudis.2021.04.023_b1115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-0030-1253455","article-title":"Targeting antioxidant and antithrombotic biotherapeutics to endothelium","volume":"36","author":"Carnemolla","year":"2010","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2021.04.023_b1120","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1182\/blood-2005-05-2002","article-title":"Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature","volume":"106","author":"Ding","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b1125","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/blood-2002-09-2853","article-title":"ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface","volume":"101","author":"Murciano","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b1130","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1124\/jpet.107.120535","article-title":"Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema","volume":"321","author":"Danielyan","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2021.04.023_b1135","doi-asserted-by":"crossref","first-page":"11577","DOI":"10.1096\/fj.201902515RR","article-title":"Bivalent engagement of endothelial surface antigens is critical to prolonged surface targeting and protein delivery in vivo","volume":"34","author":"Kiseleva","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2021.04.023_b1140","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/s41598-018-20027-7","article-title":"Vascular endothelial effects of collaborative binding to platelet\/endothelial cell adhesion molecule-1 (PECAM-1)","volume":"8","author":"Kiseleva","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2021.04.023_b1145","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/bloodadvances.2017007229","article-title":"ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model","volume":"1","author":"Greineder","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.drudis.2021.04.023_b1150","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1096\/fj.15-271213","article-title":"Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect","volume":"29","author":"Greineder","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2021.04.023_b1155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080110","article-title":"Vascular immunotargeting to endothelial determinant ICAM-1 enables optimal partnering of recombinant scFv-thrombomodulin fusion with endogenous cofactor","volume":"8","author":"Greineder","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2021.04.023_b1160","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood-2007-07-103002","article-title":"Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature","volume":"111","author":"Ding","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b1165","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0022-3565(25)21218-6","article-title":"Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature","volume":"279","author":"Muzykantov","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2021.04.023_b1170","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/ajrccm.164.7.2010076","article-title":"Vascular immunotargeting to endothelial surface in a specific macrodomain in alveolar capillaries","volume":"164","author":"Murciano","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.drudis.2021.04.023_b1175","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1073\/pnas.1912012117","article-title":"Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier","volume":"117","author":"Marcos-Contreras","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drudis.2021.04.023_b1180","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1073\/pnas.0511219103","article-title":"Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds","volume":"103","author":"Pilch","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drudis.2021.04.023_b1185","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2010-03-274258","article-title":"Nanoparticle-induced vascular blockade in human prostate cancer","volume":"116","author":"Agemy","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.04.023_b1190","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1021\/acsnano.5b06025","article-title":"Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage","volume":"10","author":"Morgan","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2021.04.023_b1195","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1021\/acsnano.9b09243","article-title":"Development of optimized tissue-factor-targeted peptide amphiphile nanofibers to slow noncompressible torso hemorrhage","volume":"14","author":"Klein","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2021.04.023_b1200","doi-asserted-by":"crossref","first-page":"10139","DOI":"10.1021\/nn502947b","article-title":"Clot-targeted micellar formulation improves anticoagulation efficacy of bivalirudin","volume":"8","author":"She","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2021.04.023_b1205","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2007-969033","article-title":"Single-chain antibodies as new antithrombotic drugs","volume":"33","author":"Hagemeyer","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2021.04.023_b1210","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1172\/JCI110778","article-title":"Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration","volume":"71","author":"Collen","year":"1983","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2021.04.023_b1215","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-0038-1657284","article-title":"Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo","volume":"48","author":"Collen","year":"1982","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2021.04.023_b1220","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1161\/01.CIR.82.5.1874","article-title":"Can plasminogen activators be improved?","volume":"82","author":"Haber","year":"1990","journal-title":"Circulation"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621002105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621002105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:55:00Z","timestamp":1761224100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621002105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":244,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1359644621002105"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.04.023","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of thrombosis and research progress on targeted antithrombotic drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}